- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China | ||
| Di | Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago | ||
| Di | Immedica overcomes prior FDA rebuke for ultrarare disease med to score new approval | ||
| 23.02. | AbbVie advances US expansion with $380M for 2 new North Chicago API plants | ||
| 23.02. | Roche halts development of Enspryng in Duchenne muscular dystrophy | ||
| 23.02. | Europe pumps brakes on US trade deal after Supreme Court decision, Trump tirade | ||
| 23.02. | Bayer sues J&J over 'deeply flawed' promotional claims touting Erleada over Nubeqa | ||
| 23.02. | Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months | ||
| 23.02. | CDMO Bora locks in 5-year, $250M production agreement with GSK | ||
| 23.02. | Girding against Keytruda cliff, Merck splits oncology into standalone business unit | ||
| 23.02. | Fortress sells FDA voucher for $205M after Zycubo approval last month | ||
| 20.02. | Catalent cuts staff by 96 in another round of layoffs in Maryland | ||
| 20.02. | Novo Nordisk nominates 2 industry vets to board in latest leadership shake-up | ||
| 20.02. | Supreme Court steps in: Trump's emergency tariffs thrown out | ||
| 20.02. | Fierce Pharma Asia-Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novo's Ozempic China sales dip | ||
| 20.02. | AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up | ||
| 20.02. | Roche looks to divest its former blockbuster antibiotic amid EU generics woes | ||
| 20.02. | Novartis plots sale of India unit while maintaining separate commercial, R&D business in country | ||
| 19.02. | Amid CDC upheaval, key vaccine panel won't convene February meeting | ||
| 19.02. | Manus Bio scores $15M US contract for domestic supply of flu drug component | ||
| 19.02. | Madrigal embraces Novo competition as Rezdiffra narrowly misses $1B mark in '25 | ||
| 19.02. | Insmed CEO explains 'audacious' $1B projection for 2026 sales of Brinsupri | ||
| 19.02. | FDA untitled letter lambastes efficacy claims in ad for J&J's Tremfya | ||
| 19.02. | Merck to seek 2nd-season RSV nod for Enflonsia in hot pursuit of Sanofi, AstraZeneca's Beyfortus | ||
| 18.02. | Can Trump pull off his MFN drug pricing plan? Former Biden advisor weighs in |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.